NYSE:LLYPharmaceuticals
Eli Lilly (NYSE:LLY) Wins Approval For Alzheimer's Drug Kisunla In Australia
Eli Lilly (NYSE:LLY) witnessed a modest 1.31% increase in its share price over the past week, coinciding with the Australian Therapeutic Goods Administration's approval of Kisunla, its novel Alzheimer's treatment, potentially adding positive investor sentiment. This development is significant given the growing Alzheimer's population in Australia. While the broader market faced a 1.1% decline amid fiscal policy concerns, Eli Lilly’s news likely provided a counterbalancing effect, helping it...